Abstract
The Amazon rainforest has wide and unique biodiversity, which is an important source of
natural products for the development of drugs. Neglected tropical diseases (NTDs) represent a major
health problem as they affect over 1 billion people, especially vulnerable populations living in tropical
and subtropical regions. Currently available drugs are generally inadequate for the majority of these
diseases, thus, there is an urgent need for new treatments. The present review aims to summarize upto-
date and comprehensive information on the efficacy of the Amazon plants, in treating certainneglected
tropical diseases. According to the literature information, several compounds (phenolics, alkaloids,
terpenoids and steroids, among others) which were isolated from plants of the Amazon forest
showed in vtro activity against Leishmania sp., Trypanosoma cruzi, the parasites responsible for
leishmaniasis and Chagas disease, respectively. Moreover, extracts and essential oil from certain
plants were reported to have mosquito repellent and insecticidal activities against Aedes aegypti, the
vector of dengue, and chikungunya. This review demonstrated that the Amazonian rainforest is endowed
with pharmacologically active plants which can be used as a starting point for the development
of new drugs against NTDs, such as leishmaniasis, Chagas disease, dengue, and chikungunya.
Keywords:
Neglected tropical diseases, amazon rainforest, biodiversity, natural products, drug design, drug discovery.
Graphical Abstract
[4]
Gil, E.S.; Paula, J.R.; Nascimento, F.R.F.; Bezerra, J.C.B. Natural products with leishmanicidal potential. Rev. Cienc. Farm. Basica Apl., 2008, 29, 223-230.
[5]
Wang, J.; Peng, Q.; Li, G. New compounds of natural resources in 2008. Afr. J. Biotechnol., 2009, 8, 4299-4307.
[10]
Moreira, R da CR.; Rebelo, J.M.M.; Gama, M.E.A.; Costa, J.M. L knowledge level about of American tegumentary leishmaniasis (ATL) and use of alternative therapies in an endemic area in the Amazon Region in the State of Maranhão, Brazil. Cad Saúde Pública / Ministério Da Saúde. Fundação Oswaldo Cruz Esc Nac Saúde Pública, 2002, 18, 187-195.
[39]
M., Netto E; Tada, MS.; Golightly, L.; Kalter, DC; Lago, E; Barreto, AC Conceitos de uma população local a respeito da leishmaniose mu-cocutânea em uma área endêmica. Rev. Soc. Bras. Med. Trop., 1985, 18, 33-37.
[46]
Calderon, L de A.; Silva-Jardim, I.; Zuliani, J.P. Silva, A de A e; Ciancaglini, P; Silva, LHP da Amazonian biodiversity: A view of drug development for leishmaniasis and malaria. J. Brazil. Chem. Soc., 2009, 20, 1011-1023.
[57]
Behrens, M.D.; Tellis, C.J.M. Chagas, MdS. Arrabidaea chica (Humb. & Bonpl.) B. Verlot; Bignoniaceae, 2012.
[81]
Lawrence, P.K.; Koundal, K.R. Plant protease inhibitors in control
of phytophagous insects. In: Electron. J. Biotechnol, 2002, 5, p.
v.5 n.1..
[97]
Patiño, A.C.; López, J.; Aristizábal, M.; Quintana, J.C. inhibitory Effect extract of Renealmia alpinia Rottb. Maas (Zingiberaceae) on the poison of bothrops asper (mapaná). Biomedica., 2012, 32(3), 365-374.